Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 14;3(1):dlaa104.
doi: 10.1093/jacamr/dlaa104. eCollection 2021 Mar.

Measures used to assess the burden of ESBL-producing Escherichia coli infections in humans: a scoping review

Kathryn L McDonald  1   2 , Sarah Garland  3 , Carolee A Carson  1 , Kimberly Gibbens  4 , E Jane Parmley  1   4 , Rita Finley  1 , Melissa C MacKinnon  1   4
Affiliations

Measures used to assess the burden of ESBL-producing Escherichia coli infections in humans: a scoping review

Kathryn L McDonald et al. JAC Antimicrob Resist. .

Abstract

Background: ESBL-producing bacteria pose a serious challenge to both clinical care and public health. There is no standard measure of the burden of illness (BOI) of ESBL-producing Escherichia coli (ESBL-EC) in the published literature, indicating a need to synthesize available BOI data to provide an overall understanding of the impact of ESBL-EC infections on human health.

Objectives: To summarize the characteristics of BOI reporting in the ESBL-EC literature to (i) describe how BOI associated with antimicrobial resistance (AMR) is measured and reported; (ii) summarize differences in other aspects of reporting between studies; and (iii) highlight the common themes in research objectives and their relation to ESBL-EC BOI.

Methods and results: Two literature searches, run in 2013 and 2018, were conducted to capture published studies evaluating the BOI associated with ESBL-EC infections in humans. These searches identified 1723 potentially relevant titles and abstracts. After relevance screening of titles and abstracts and review of full texts, 27 studies were included for qualitative data synthesis. This review identified variability in the reporting and use of BOI measures, study characteristics, definitions and laboratory methods for identifying ESBL-EC infections.

Conclusions: Decision makers often require BOI data to make science-based decisions for the implementation of surveillance activities or risk reduction policies. Similarly, AMR BOI measures are important components of risk analyses and economic evaluations of AMR. This review highlights many limitations to current ESBL-EC BOI reporting, which, if improved upon, will ensure data accessibility and usefulness for ESBL-EC BOI researchers, decision makers and clinicians.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Literature search and screening process, adapted from the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) for a scoping review of BOI measures related to ESBL-producing E. coli infections in humans.
Figure 2.
Figure 2.
Years of data collection and publication period for data included in the scoping review of BOI measures related to ESBL-producing E. coli infections in humans. aFrequency of Data Collection: each year of data during a multi-year collection period is recorded as one value.
See this image and copyright information in PMC

References

    1. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933–51. - PMC - PubMed
    1. Schwaber MJ, Navon-Venezia S, Kaye KS. et al. Clinical and economic impact of bacteremia with extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006; 50: 1257–62. - PMC - PubMed
    1. Ambler R, Coulson F. A standard numbering scheme for the Class A β-lactamases. Biochem J 1991; 276: 269–72. - PMC - PubMed
    1. Bush K, Jacoby GA, Medeiros AAA. Functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211–33. - PMC - PubMed
    1. Drawz SM, Bonomo RA. Three decades of β-lactamase inhibitors. Clin Microbiol Rev 2010; 23: 160–201. - PMC - PubMed

Publication types

LinkOut - more resources